Cargando…
Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer
BACKGROUND: The TP53 tumor suppressor gene plays an important role in preventing and inhibiting the growth of tumor by regulating cell cycle, apoptosis and DNA repair. Meanwhile, the TP53 gene is one of the most frequently altered gene in non-small cell lung cancer (NSCLC) patients. Mutant TP53 (TP5...
Autores principales: | Fan, Zhisong, Zhang, Qi, Feng, Li, Wang, Long, Zhou, Xinliang, Han, Jing, Li, Dan, Liu, Jiayin, Zhang, Xue, Zuo, Jing, Zou, Xiao, Cai, Yiran, Sun, Ying, Wang, Yudong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908146/ https://www.ncbi.nlm.nih.gov/pubmed/35280362 http://dx.doi.org/10.21037/atm-22-412 |
Ejemplares similares
-
Joint effect of THBS2 and VCAN accelerating the poor prognosis of gastric cancer
por: Wang, Long, et al.
Publicado: (2023) -
Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020) -
Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report
por: Li, Dan, et al.
Publicado: (2022) -
The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
por: Wang, Long, et al.
Publicado: (2021) -
Bifidobacterium breve predicts the efficacy of anti‐PD‐1 immunotherapy combined with chemotherapy in Chinese NSCLC patients
por: Zhao, Honghui, et al.
Publicado: (2022)